Therapeutic prostate cancer vaccines: A review of the latest developments

Current Opinion in Investigational Drugs

Volumn 9, Issue 12, 2008, Pages 1296-1301

  Mohebtash, M ^a   Madan, R A ^a   Gulley, J L ^a   Arlen, P M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Castration resistant prostate cancer; Dendritic cell; GVAX; HER 2; Poxviral vector; Prostate cancer; Prostate specific antigen; Vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; DENDRITIC CELL VACCINE; DOCETAXEL; E 75; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; NILUTAMIDE; ONYVAX P; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LOW DRUG DOSE; PROSTATE CANCER; REVIEW; TUMOR IMMUNOLOGY;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 57349144373     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/ neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 107(4):477-484.
2. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY et al: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 6(5):1632-1638.
3. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W et al: Recombinant vaccinia virus encoding human MUC-1 and IL-2 as immunotherapy in patients with breast cancer. J Immunother (2000) 23(5):570-580.
4. Boehncke WH, Takeshita T, Pendleton CD, Houghten RA, Sadegh-Nasseri S, Racioppi L, Berzofsky JA, Germain RN: The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T-cell recognition. J Immunol (1993) 150(5):331-41.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin (2008) 58(2):71-96.
6. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. J Am Med Assoc (2005) 294(2):238-244.
7. Tani K, Azuma M, Nakazaki Y, Oyaizu N, Hase H, Ohata J, Takahashi K, OiwaMonna M, Hanazawa K, Wakumoto Y, Kawai K et al: Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol Ther (2004) 10(4):799-816.
8. Schlom J, Arlen PM, Gulley JL: Cancer vaccines: Moving beyond current paradigms. Clin Cancer Res (2007) 13(13):3776-3782.
9. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC-8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 24(19):3089-3094. •• A phase III, placebo-controlled clinical trial of Provenge in 127 men with asymptomatic hormone-refractory prostate cancer. The median OS was 25.9 months in patients randomized to receive the vaccine, compared with 21.4 months in those receiving placebo (p = 0.01).
10. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M et al: Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 13(13):3883-3891.
11. Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG: Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res (2003) 63(17):5505-5512.
12. Simons JW, Sacks N: Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol (2006) 24(5):419-424.
13. Cell Genesys Inc: Cell Genesys initiates second phase III clinical trial of GVAX vaccine for prostate cancer. Press Release (2005):July 05.
14. Cell Genesys Inc: Cell Genesys initiates phase III clinical trial of GVAX prostate cancer vaccine. Press Release (2004):July 15.
15. Cell Genesys Inc: Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer. Press Release (2008):August 27.
16. Cell Genesys Inc: Cell Genesys reconfirms ongoing plans with FDA for phase III program for GVAX immunotherapy for prostate cancer while on partial clinical hold. Press Release (2008):September 11.
17. Laheru D, Yeo C, Biedrzycki B, Solt S, Lutz E, Onners B, Tartakovsky I, Herman J, Hruban R, Piantadosi S, Jaffee E: A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol (2007) 25(Suppl 18):Abs 3010.
18. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H: Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res (2005) 11(12):4469-4478.
19. Doehn C, Bohmer T, Jocham D: Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther (2005) 7(5):511-519.
20. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 18(23):3894-3903.
21. Onyvax Ltd: Onyvax European phase IIb clinical trial completes enrolment. Press Release (2008):March 17.
22. Onyvax Ltd: Phase IIb clinical trial of Onyvax-P in early stage prostate cancer initiated in United States. Press Release (2007):September 26.
23. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: The near future. Int J Cancer (2001) 94(4):459-473.
24. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer (2000) 89(12):2646- 2654.
25. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C et al: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann Oncol (2006) 17(4):563-570.
26. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E et al: Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 178(4 Pt 1):1515-1520.
27. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R: Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood (2001) 97(5):1370-1377.
28. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG et al: Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 11(12):4430-4436.
29. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K et al: Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 12(3 Pt 1):878-887.
30. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N et al: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res (2004) 10(14):4699-4708.
31. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res (2003) 63(9):2127-2133.
32. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol (2001) 166(5):2953-2960.
33. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T-cells and mediate tumor regression. Cancer Res (2001) 61(23):8513-8519.
34. Carroll MW, Moss B: Poxviruses as expression vectors. Curr Opin Biotechnol (1997) 8(5):573-577.
35. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 59(22):5800-5807.
36. Wingren AG, Parra E, Varga M, Kalland T, Sjogren HO, Hedlund G, Dohlsten M: T-cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T-cell profiles. Crit Rev Immunol (1995) 15(3-4):235-253.
37. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 22(11):2122- 2132. • In this phase II clinical trial, patients were randomized to receive recombinant poxvirus vectors with the gene for PSA. There was a substantial difference in PSA PFS, favoring the use of vaccinia priming and avipox vector boosting.
38. Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM: Analysis of survival in patients with nonmetastatic castrate-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 14(14):4526-4531. •• Hormone-refractory prostate cancer patients with no measurable disease on scans were randomized to receive a poxvirus vector PSA vaccine versus the androgen receptor antagonist nilutamide. The results demonstrated an overall survival benefit for patients randomized to receive vaccine therapy.
39. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E et al: Clinical safety of a viral vector-based prostate cancer vaccine strategy. J Urol (2007) 178(4 Pt 1):1515-1520.
40. Madan R, Gulley J, Dahut W, Tsang K, Schlom J, Arlen P: Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC). ASCO Genitourinary Cancers Symposium (2008):Abs 190.
41. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4(3):321-327.
42. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW et al: Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res (2007) 13(21):6386-6395.
43. Borrello I, Pardoll D: GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev (2002) 13(2):185-193.
44. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 20(11):2624- 2632.
45. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S: Clinical trial results of a HER-2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol (2005) 23(30):7536-7545. •• HLA-A2-positive, node-positive, disease-free patients with breast cancer were administered E75. HLA-A2-negative patients were monitored as controls. All vaccinated patients demonstrated clonal expansion of E75-specific CD8+T-cells that lysed HER-2/neu-expressing tumor cells. A reduced recurrence rate was observed in vaccinated patients compared with controls (median: 11 versus 8 months, respectively).
46. Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE: Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER-2/neu vaccine-based immunotherapy for breast cancer: A pilot study. Ann Surg Oncol (2007) 14(12):3359-3368.
47. Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S et al: Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res (2005) 11(20):7470-7479.
48. Apthera Inc: Positive phase II clinical trial results with HER-2/neu vaccine. Press Release (2006): December 14.
49. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdona S, Giordano A, Giuliano M, Labianca R et al: Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A phase 2 study. Eur Urol (2008): doi:10.1016/j.eururo.2008. 01.082.
50. Gerritsen W, van den Eertwegh A, de Gruijl T, van den Berg H, Scheper R, Sacks N, Lowy I, Stankevich E, Hege K: Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol (2008) 26:Abs 5146.